SPRO — Spero Therapeutics, Inc.

Is SPRO overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Neutral As of October 3, 2026

Spero Therapeutics, Inc. (SPRO) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Biotechnology) last closed at $1.19. The rating moved from Overbought to Neutral on October 3, 2026.

AI analysis

Spero Therapeutics, Inc. (SPRO) is a low‑liquidity, development‑stage specialty pharma equity where value is concentrated in a small number of clinical assets and near‑term financing prospects. In the current risk‑off market environment and given active policy pressure on drug pricing, downside from dilution, clinical setbacks, or delayed development is the dominant near‑term path. Upside hinges on clear positive clinical readouts, partnering/licensing activity, or a favorable financing event; absent those catalysts, market appetite appears limited and volatility is likely to persist.

Key factors

  • Very limited market capitalization and liquidity increase susceptibility to volatile moves and thin-order book price impacts
  • Unclear near-term cash runway and financing/dilution risk for a small specialty pharma without broad commercial revenues
  • Sector headwinds: payer and policy pressure on drug pricing (Medicare IRA) increases revenue and pricing risk for specialty therapeutics
  • Macro risk-off tone and muted volumes reduce odds of positive equity re-ratings absent material clinical or corporate catalysts
  • Binary clinical and regulatory outcomes remain the primary upside driver; a positive readout or strategic partnership could lift valuation quickly
  • Comparative sector strength for late-stage rare-disease biologics highlights investor preference for durable, late-stage assets versus early-stage programs

Risks

  • Further share dilution from equity raises or at-the-market offerings that compress existing shareholder value
  • Clinical trial failures or delays that remove the primary value drivers for a development-stage company
  • Adverse regulatory decisions or facility/inspection issues that could slow development timelines
  • Weak trading liquidity leading to large intraday swings and execution risk for institutional investors
  • Negative effects from Medicare drug‑price negotiation, payer access restrictions, or unfavorable pricing outcomes
  • Broader market risk-off episodes or tightening credit conditions that disproportionately impact small biotech equities

See today's live rating, score and targets

Members see the live hourly rating for SPRO — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.